Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.

Autor:	Abu Hassan SO; Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Department of Clinical Research, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Department of Clinical Research, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark., Nielsen DL; Department of Oncology, Herlev & Gentofte Hospital, University of Copenhagen, Herlev, Denmark.; Department of Oncology, Herlev & Gentofte Hospital, University of Copenhagen, Herlev, Denmark., Tuxen MK; Department of Oncology, Herlev & Gentofte Hospital, University of Copenhagen, Herlev, Denmark.; Department of Oncology, Herlev & Gentofte Hospital, University of Copenhagen, Herlev, Denmark., Petersen PH; Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Norwegian Quality Improvement Primary Care Laboratories (NOKLUS), Section for General Practice, University of Bergen, Bergen, Norway.; Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Norwegian Quality Improvement Primary Care Laboratories (NOKLUS), Section for General Practice, University of Bergen, Bergen, Norway., Sölétormos G; Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Department of Clinical Research, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Department of Clinical Biochemistry, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.; Department of Clinical Research, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2017 Jul 18; Vol. 3 (3), pp. FSO216. Date of Electronic Publication: 2017 Jul 18 (Print Publication: 2017).
DOI:	10.4155/fsoa-2017-0023
Abstrakt:	Aim: To investigate seven CA125 criteria to monitor progressive ovarian cancer among patients with stage IC-IV disease. Materials & Methods: Four criteria were used to asses CA125 increments starting from concentrations ≥35 U/ml and three criteria to asses increments starting from concentrations <35 U/ml. Results: A total of 231 patients were allocated to CA125 monitoring. The performances of the CA125 criteria were similar with sensitivities of 30-55%, negative predictive values of 28-46%, positive predictive values of 90-100% and median lead times of 26-87 days. Conclusion: The criteria showed low sensitivity and inability to exclude progressive ovarian cancer. The study suggests that CA125 information cannot stand alone but should be considered used in conjunction with other investigative procedures. Competing Interests: Financial & competing interests disclosure The authors would like to thank Nordsjællands Hospital, Helen Rude's Fond, Olga Bryde Nielsen's Fond, Ingeniør August Frederik Wedell Erichsen's Legat and Fonden til Fremme af Klinisk Cancerforskning for financial support. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu